EE04193B1 - Triasolo[4,5-d]pürimidiini ühendid, neid sisaldavad ravimkoostised ja nende valmistamise meetodid - Google Patents

Triasolo[4,5-d]pürimidiini ühendid, neid sisaldavad ravimkoostised ja nende valmistamise meetodid

Info

Publication number
EE04193B1
EE04193B1 EEP200000044A EEP200000044A EE04193B1 EE 04193 B1 EE04193 B1 EE 04193B1 EE P200000044 A EEP200000044 A EE P200000044A EE P200000044 A EEP200000044 A EE P200000044A EE 04193 B1 EE04193 B1 EE 04193B1
Authority
EE
Estonia
Prior art keywords
triazolo
preparation
methods
pharmaceutical compositions
compositions containing
Prior art date
Application number
EEP200000044A
Other languages
English (en)
Inventor
Guile Simon
Ingall Anthony
Springthorpe Brian
Willis Paul
Original Assignee
Astra Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04193(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9702775A external-priority patent/SE9702775D0/xx
Priority claimed from SE9702773A external-priority patent/SE9702773D0/xx
Application filed by Astra Pharmaceuticals Limited filed Critical Astra Pharmaceuticals Limited
Publication of EE200000044A publication Critical patent/EE200000044A/et
Publication of EE04193B1 publication Critical patent/EE04193B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EEP200000044A 1997-07-22 1998-07-15 Triasolo[4,5-d]pürimidiini ühendid, neid sisaldavad ravimkoostised ja nende valmistamise meetodid EE04193B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702775A SE9702775D0 (sv) 1997-07-22 1997-07-22 Novel compounds
SE9702773A SE9702773D0 (sv) 1997-07-22 1997-07-22 Novel compounds
PCT/SE1998/001393 WO1999005143A1 (en) 1997-07-22 1998-07-15 Novel compounds

Publications (2)

Publication Number Publication Date
EE200000044A EE200000044A (et) 2000-10-16
EE04193B1 true EE04193B1 (et) 2003-12-15

Family

ID=26663042

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000044A EE04193B1 (et) 1997-07-22 1998-07-15 Triasolo[4,5-d]pürimidiini ühendid, neid sisaldavad ravimkoostised ja nende valmistamise meetodid

Country Status (30)

Country Link
EP (1) EP0996621B1 (et)
JP (1) JP4187406B2 (et)
KR (2) KR100535837B1 (et)
CN (1) CN1154650C (et)
AR (2) AR017014A1 (et)
AT (1) ATE251161T1 (et)
AU (1) AU745381B2 (et)
BR (1) BR9810802B1 (et)
CA (1) CA2296665C (et)
CZ (1) CZ302629B6 (et)
DE (1) DE69818668T2 (et)
DK (1) DK0996621T3 (et)
EE (1) EE04193B1 (et)
EG (1) EG24412A (et)
ES (1) ES2207846T3 (et)
HU (1) HU230074B1 (et)
IL (2) IL133959A0 (et)
IS (1) IS2236B (et)
MY (1) MY123196A (et)
NO (1) NO315854B1 (et)
NZ (1) NZ502381A (et)
PL (1) PL200325B1 (et)
PT (1) PT996621E (et)
RU (1) RU2225407C2 (et)
SA (1) SA98190487B1 (et)
SK (1) SK284199B6 (et)
TR (1) TR200000197T2 (et)
TW (1) TW530058B (et)
UA (1) UA66801C2 (et)
WO (1) WO1999005143A1 (et)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013487D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Novel process
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
IT1317049B1 (it) * 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
SE0004098D0 (sv) * 2000-11-09 2000-11-09 Astrazeneca Ab Novel compounds
SE0004099D0 (sv) 2000-11-09 2000-11-09 Astrazeneca Ab Novel compounds
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
DE602004027409D1 (de) 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
SE0401001D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
GB0615620D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
JP2010508350A (ja) 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
KR101669297B1 (ko) 2008-09-09 2016-10-25 아스트라제네카 아베 [1Ｓ-[1-알파,2-알파,3-베타(1Ｓ*,2Ｒ*),5-베타]]-3-[7-[2-(3,4-디플루오로페닐)-사이클로프로필아미노]-5-(프로필티오)-3Ｈ-1,2,3-트리아졸로[4,5-ｄ]피리미딘-3-일]-5-(2-하이드록시에톡시)사이클로펜탄-1,2-디올의 제조 방법 및 그 중간체
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
EP2305376A1 (en) 2009-09-23 2011-04-06 Lonza Ltd. Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
US8883802B2 (en) 2009-12-03 2014-11-11 Astrazeneca Ab Co-crystals of a triazolo [4,5-D] pyrimide platelet aggregation inhibitor
ES2550033T3 (es) 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
WO2011101740A1 (en) 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
WO2011132083A2 (en) 2010-04-20 2011-10-27 Actavis Group Ptc Ehf Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
CN103003231A (zh) 2010-06-30 2013-03-27 阿特维斯集团公司 制备苯基环丙基胺衍生物的新方法及其用于制备替卡格雷的用途
DK2598482T3 (en) 2010-07-29 2018-06-14 Oryzon Genomics Sa ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (en) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
CA2859743A1 (en) 2010-12-20 2012-06-28 Actavis Group Ptc Ehf Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CN102731510B (zh) * 2011-04-07 2015-12-16 博瑞生物医药（苏州）股份有限公司 替卡格雷的衍生物、制备方法及其药物用途
JP2014516982A (ja) 2011-06-01 2014-07-17 アストラゼネカ アクチボラグ 新規なチカグレロル共結晶
CA2839057A1 (en) 2011-06-15 2012-12-20 Actavis Group Ptc Ehf Improved process for preparing cyclopentylamine derivatives and intermediates thereof
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
HRP20180466T1 (hr) * 2011-10-27 2018-07-27 Lek Pharmaceuticals D.D. Sinteza spojeva triazolopirimidina
EP2589587A1 (en) 2011-11-04 2013-05-08 Chemo Ibérica, S.A. Synthesis of nitrogen substituted cyclopropanes
JP2015500219A (ja) 2011-11-30 2015-01-05 アクタビス・グループ・ピーティーシー・イーエイチエフ 新規な結晶形を有するチカグレロル及びその調製方法
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
US9233966B2 (en) 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN102675321B (zh) * 2012-05-11 2014-12-10 上海皓元化学科技有限公司 一种替卡格雷的制备方法
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
CZ2012705A3 (cs) 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
CN103965198A (zh) * 2013-02-05 2014-08-06 郝聪梅 替卡格雷的中间体及其制备方法以及利用该中间体制备替卡格雷的方法
CN103183679A (zh) * 2013-03-20 2013-07-03 西藏海思科药业集团股份有限公司 抗凝血化合物及其应用
CN104098553B (zh) * 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
CA2913326A1 (en) 2013-05-29 2014-12-04 Ratiopharm Gmbh Solid pharmaceutical dosage form
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
CN103588751B (zh) * 2013-11-07 2014-12-17 苏州明锐医药科技有限公司 替格瑞洛中间体的制备方法
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
US10011605B2 (en) 2014-06-18 2018-07-03 Flamma Spa Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds
CN105272985B (zh) * 2014-06-24 2017-11-21 珠海联邦制药股份有限公司 三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物
RU2021125449A (ru) 2014-10-01 2021-09-16 Медиммьюн Лимитед Антитела к тикагрелору и способы применения
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105985346B (zh) * 2015-03-06 2019-10-18 苏州朗科生物技术股份有限公司 一种新的替格瑞洛化合物制备方法及其中间体化合物
TR201601835A2 (tr) 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
US9840481B2 (en) 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
WO2018167447A1 (en) 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
CN107141298A (zh) * 2017-07-24 2017-09-08 苏州信恩医药科技有限公司 一种替格瑞洛的合成方法
TWI641327B (zh) * 2017-09-30 2018-11-21 双邦實業股份有限公司 Socks that are comfortable and comfortable to wear
EP3527571A1 (en) * 2018-02-14 2019-08-21 Université de Liège Pyrimidine derivatives for prevention and treatment of bacterial infection
EP3852617B1 (en) 2018-09-20 2025-09-10 SFJ Pharma X, Inc. Use of antibody fragments for reversing ticagrelor activity
WO2021096444A1 (en) 2019-11-13 2021-05-20 Santa Farma İlaç Sanayi̇ A.Ş. Pharmaceutical compositions comprising ticagrelor
WO2023213198A1 (zh) * 2022-05-04 2023-11-09 华东师范大学 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂
CN114805367B (zh) * 2022-05-24 2023-04-07 郑州大学 一种三氮唑并嘧啶类衍生物及其制备方法和应用
CN115710275B (zh) * 2022-11-21 2024-02-02 河南中医药大学 一种嘧啶-tcp类化合物、制备方法和医药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
MX16165A (es) * 1988-05-25 1994-02-28 Dow Chemical Co Alcoxi-1,2,4-triazolo[1,5-c]pirimidin-2-sulfonamidas, procedimiento para su preparacion e intermediarios.
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
WO1997003084A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
US6297232B1 (en) * 1996-12-20 2001-10-02 Astrazeneca Ab Triazolo[4,5-D]pyrimidinyl derivatives and their use as medicaments

Also Published As

Publication number Publication date
WO1999005143A1 (en) 1999-02-04
CN1154650C (zh) 2004-06-23
NO20000312D0 (no) 2000-01-21
KR20010022083A (ko) 2001-03-15
IS2236B (is) 2007-05-15
IL133959A0 (en) 2001-04-30
AR017014A1 (es) 2001-08-22
ES2207846T3 (es) 2004-06-01
AR077553A2 (es) 2011-09-07
BR9810802A (pt) 2000-09-12
HU230074B1 (hu) 2015-06-29
PL200325B1 (pl) 2008-12-31
DE69818668T2 (de) 2004-08-12
EE200000044A (et) 2000-10-16
MY123196A (en) 2006-05-31
EP0996621B1 (en) 2003-10-01
KR20050084540A (ko) 2005-08-26
AU745381B2 (en) 2002-03-21
BR9810802B1 (pt) 2010-10-19
SK188199A3 (en) 2000-10-09
HUP0004333A3 (en) 2001-11-28
ATE251161T1 (de) 2003-10-15
NO315854B1 (no) 2003-11-03
TR200000197T2 (tr) 2000-06-21
JP4187406B2 (ja) 2008-11-26
CA2296665A1 (en) 1999-02-04
EG24412A (en) 2009-05-25
IS5354A (is) 2000-01-20
SK284199B6 (sk) 2004-10-05
DE69818668D1 (de) 2003-11-06
CN1270590A (zh) 2000-10-18
PT996621E (pt) 2004-02-27
IL133959A (en) 2007-10-31
CZ302629B6 (cs) 2011-08-10
NZ502381A (en) 2001-12-21
DK0996621T3 (da) 2004-02-02
SA98190487B1 (ar) 2006-08-20
TW530058B (en) 2003-05-01
PL338516A1 (en) 2000-11-06
UA66801C2 (uk) 2004-06-15
KR100535837B1 (ko) 2006-01-12
NO20000312L (no) 2000-03-21
HK1026421A1 (en) 2000-12-15
EP0996621A1 (en) 2000-05-03
JP2001510842A (ja) 2001-08-07
AU8370698A (en) 1999-02-16
RU2225407C2 (ru) 2004-03-10
HUP0004333A2 (hu) 2001-04-28
CZ2000233A3 (cs) 2000-07-12
CA2296665C (en) 2008-06-10

Similar Documents

Publication Publication Date Title
EE9800278A (et) Pürimido[5,4-d]pürimidiinid, neid ühendeid sisaldavad ravimid, nende kasutamine ja valmistamismeetodid
HUP0100202A3 (en) Novel triazolo[4,5-d]pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0105081A3 (en) Triazolo[4,5-d]pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0004333A3 (en) Novel triazolo [4,5-d] pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing thereof
EE9800289A (et) Pürimido[5,4-d]pürimidiinid, neid ühendeid sisaldavad ravimid, nende kasutamine ja valmistamismeetodid
EE05181B1 (et) Prasolo[4,3-d]primidiini derivaadid, neid sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja meetodid nende valmistamiseks
FI970968L (fi) Pyrimido/5,4-d/pyrimidiinit, näitä yhdisteitä sisältävät lääkeaineet, niiden käyttö ja menetelmä niiden valmistamiseksi
IL128869A (en) ARYSULFONYL-SUBSTITUTED-PYRAZOLO [1,5-a]-PYRIMIDINE AND PYRAZOLO [1,5-a] [1, 3, 5]-TRIAZINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0001507A3 (en) Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0204246A3 (en) Novel thiazolo[4,5-d]pyrimidine compounds, process for their preparation, pharmaceutical compositions containing them and their use
DE69827419D1 (de) Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-Pyrazolo[1,5-b]Pyridazin Derivate
HUP9801587A3 (en) 5h-thiazolo[3,2-a]pyrimidine derivatives, process for their preparation, intermediates, use of the compounds and pharmaceutical compositions containing them
HUP0002104A3 (en) Pyrazolo[3,4-d]pyrimidinedione derivatives, process for their preparation and pharmaceutical compositions containing them
EE04282B1 (et) Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon
HUP0204431A3 (en) 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use, process for their preparation and pharmaceutical compositions containing them
EE04399B1 (et) Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis
IL127056A (en) Aryl pyrimidine derivatives, their preparation and pharmaceutical compositions comprising them
EE05034B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende valmistamise meetodid
HUP0103472A3 (en) Pyrrolo[2,3-d]pyrimidine derivatives and pharmaceutical compositions containing the same
HUP0104199A3 (en) Substituted pyrimido pyrimidinone derivatives, pharmaceutical compositions containing the same, process for the preparation thereof and intermediates
HUP0203503A3 (en) Pyrrolo[2,3-d]pirimidine compounds, pharmaceutical compositions containing them and their use
ID29514A (id) 2-ARIL-3-(HETEROARIL)-IMIDAZO [1,2-a]PIRIMIDIN TERSUBSTITUSI, DAN METODE-METODE DAN KOMPOSISI-KOMPOSISI FARMASI YANG TERKAIT
HUP0002480A3 (en) Pyrrolo[2,1-c][1,4]benzodiazepine derivatives, their use, process for their preparation and pharmaceutical compositions containing them
HUP0003826A3 (en) Novel triazolo [4,5-b] pyrimidine derivatives, process for their preparation and pharmaceutical compositions thereof
HUP0002272A3 (en) Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

AA1Y Spc filed

Free format text: PRODUCT NAME: BRILIQUE - TICAGRELOR; REG NO/DATE: K(2010)8908 03.12.2010

Spc suppl protection certif: C20110008

Filing date: 20110526

FG1Y Spc granted

Free format text: PRODUCT NAME: BRILIQUE - TICAGRELOR; REG NO/DATE: K(2010)8908 03.12.2010

Spc suppl protection certif: C20110008 00040

Filing date: 20110526

Extension date: 20230715

GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name